Six Taipei Biotechs Head to BIO 2026 with Late-Stage Assets, Precision Diagnostics, and Next-Generation Drug Delivery Platforms
核心洞察
Six Taipei-based biotech companies will showcase pipelines spanning rare neurological diseases, precision diagnostics, drug delivery, and microalgae-derived therapeutics at BIO 2026 in San Diego.
AnnJi Pharmaceutical (搜索)'s lead candidate AJ201, a Phase 3-ready androgen receptor (搜索) degrader for Kennedy's Disease (搜索), highlights Taiwan's push into late-stage clinical assets with first-in-class potential.
Leadgene Biosolutions (搜索)' NEST microbioreactor platform cuts conventional cell line development timelines by 29% to 42%, addressing critical bioprocess bottlenecks.
SAN DIEGO — The Taipei City Government is organizing a delegation of six Taipei-based biotechnology companies to the BIO International Convention 2026 in San Diego, positioning Taiwan's biotech ecosystem within global conversations around drug development, companion diagnostics, biomanufacturing, and next-generation biomedical platforms. The participating companies — AnnJi Pharmaceutical (搜索), Leadgene Biosolutions (搜索), FEBICO (搜索) (Far East Bio-Tec Co., Ltd.), PharmiGENE (搜索), TAHO Pharma (搜索), and Instant NanoBiosensors (搜索) — span therapeutics, diagnostics, CDMO services, biosensing, and bioprocess instrumentation, reflecting a sector that has moved well beyond contract services and into areas where Taiwan companies are generating original science.
The delegation arrives at a moment when global biotech faces mounting pressure to shorten development timelines, improve manufacturing scalability, and demonstrate clinically actionable differentiation in increasingly competitive markets. Healthcare systems worldwide are managing aging populations, chronic disease burden, and growing demand for personalized treatment — trends that continue reshaping investment and partnership priorities across the sector.
AnnJi Pharmaceutical Targets Kennedy's Disease with Phase 3-Ready Asset
One of the persistent challenges in rare and neurological diseases is the gap between scientific discovery and clinical-stage assets. Kennedy's Disease (搜索), a progressive polyQ neurodegenerative disorder affecting motor neurons, remains largely without disease-modifying treatment options despite years of research. AnnJi Pharmaceutical (搜索) is targeting precisely this gap.
AnnJi's lead program, AJ201, is an androgen receptor (搜索) degrader that operates through Nrf1/Nrf2/Hsf1 pathway modulation and is currently Phase 3-ready for Kennedy's Disease (搜索). The company's pipeline spans Histone Deacetylase 6 (HDAC6) inhibitors across multiple indications — including chemotherapy-induced peripheral neuropathy (搜索) (CIPN), fibrotic diseases such as idiopathic pulmonary fibrosis (搜索) (IPF), and keloid scarring — alongside additional pre-clinical programs. AnnJi's strategic approach focuses on novel small molecules with first-in-class potential, pursuing both out-licensing and in-licensing to build a portfolio positioned for global commercialization.
Leadgene Biosolutions' Dual-Platform Strategy for Bioprocess Efficiency
Upstream of the clinic, pharmaceutical and biotech workflows face a critical bottleneck: the time and resource investment required to scale cell lines and optimize bioprocesses. Leadgene Biosolutions (搜索) has deployed a dual-platform strategy to address these challenges.
For high-throughput cell line development and bioprocess optimization, the NEST series microbioreactor platform operates at the 24- and 96-well plate scale, combining programmable micro-mixing and independent incubation control with enhanced oxygen transfer efficiency. The system maintains strict process consistency while cutting conventional cell line development timelines by 29% to 42%. Complementing this is the DolphinQ series, built for long-term metabolic monitoring in academic and translational research. DolphinQ provides sampling-free, real-time tracking of dissolved oxygen, pH, oxygen consumption rate, and extracellular acidification rate across extended culture windows spanning days, weeks, or months. Together, these platforms support applications spanning cell line development, bioprocess optimization, cell and gene therapy research, immunology, infectious disease studies, oncology, and metabolic research.
PharmiGENE Advances Pharmacogenomics into Routine Care
The clinical application of pharmacogenomics has been building momentum for years, but implementation at scale in real hospital workflows remains uneven. Adverse drug reactions, including severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson Syndrome (搜索) (SJS/TEN), are among the most preventable serious harms in medicine.
PharmiGENE (搜索) has built its business model around translating HLA typing into actionable, point-of-care testing by developing PGx kits and HLA typing solutions designed to identify genetic risk factors for adverse drug reactions before patients are exposed. Its work in SCARs prevention is particularly relevant in Asian populations, where specific HLA alleles linked to drug hypersensitivity occur at higher frequencies than in other demographics. These kits are certified for In Vitro Diagnostics (IVD) use by both Taiwan and China authorities, and their inclusion in Taiwan's National Health Insurance system gives local genetic diagnostics companies a scientifically grounded, commercially viable position in the region.
TAHO Pharma and Instant NanoBiosensors: Delivery Innovation and Precision Diagnostics
TAHO Pharma (搜索) will showcase its Oral Dissolving Film (ODF) and Transdermal/Transmucosal Drug Delivery platforms, which transform established pharmaceutical compounds into patient-centric products with enhanced convenience, improved treatment adherence, and strong lifecycle management potential. The company is actively seeking global licensing, co-development, and regional commercialization partners.
Instant NanoBiosensors (搜索) addresses the urgent need for earlier detection in Alzheimer's disease (搜索) and leukemia (搜索) through its FOPPR and FONLISA biosensor technologies for highly sensitive protein biomarker detection, alongside the INVISION INLab NGS Solution — an integrated sample-to-report workflow combining automated instrumentation, proprietary reagents, and bioinformatics reporting systems.
FEBICO's Microalgae Platform Expands into Therapeutics
Far East Bio-Tec. Co., Ltd. (FEBICO (搜索)) will highlight its proprietary microalgae platform, showcasing drug candidates FB-1603 and FB-1807 — two proprietary APIs being developed for severe liver diseases including liver inflammation, injury, and fibrosis — through its sister company Febico Biomedical Corp. The company is also debuting FEM-101 (搜索), a versatile sulfated polysaccharide platform with broad-spectrum antiviral and anti-inflammatory potential that can be formulated as a nanocarrier for drug delivery and incorporated into medical dressing applications, as well as Chlorella sorokiniana extracellular vesicles for skincare and nutritional applications.
The six companies heading to San Diego represent a cross-section of where Taiwan's life sciences sector is investing: late-stage drug assets in underserved neurological indications, enabling technologies for manufacturing and diagnostic workflows, and emerging platform plays in precision diagnostics and bioactive materials. The common thread is an orientation toward international markets as the primary commercial strategy.